Bladder Cancer Specialty Channel

Bladder Cancer

Specialty Channel

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Extended Lymphadenectomy Fails to Improve Survival Outcomes for Patients With Muscle-Invasive Bladder Cancer

11/05/2024

Stephanie Holland ;

Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.

Results from the phase 2 SWOG...

11/05/2024

Oncology

News

Adjuvant Pembrolizumab for Patients With High-Risk Muscle-Invasive Urothelial Carcinoma

10/24/2024

According to the phase 3 AMBASSADOR trial, adjuvant pembrolizumab significantly improved disease-free survival among patients with high-risk muscle-invasive urothelial carcinoma.

According to the phase 3...

10/24/2024

Oncology

News

Perioperative Durvalumab Improved Survival Outcomes for Patients With Operable, Muscle-Invasive Bladder Cancer

10/24/2024

According to the phase 3 NIAGARA trial, the addition of perioperative durvalumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival among cisplatin-eligible patients with operable, muscle-invasive...

According to the phase 3 NIAGARA...

10/24/2024

Oncology

News

Optimal Rogaratinib Dose for Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Advanced Urothelial Cancer

10/23/2024

Stephanie Holland ;

According to results from the phase 1b FORT-2 study, 600 mg of rogaratinib is preferable to 800 mg among cisplatin-ineligible patients with FGFR RNA-overexpressing locally advanced or metastatic urothelial cancer being treated with...

According to results from the...

10/23/2024

Oncology

Conference Coverage

TAR-200 Plus Cetrelimab Provides Promising Clinical Benefit for Patients With Muscle-Invasive Bladder Cancer

10/23/2024

Andrea Necchi , MD;

Andrea Necchi, MD, discusses results from the SunRISe-4 study which assessed the addition of TAR-200 to neoadjuvant cetrelimab in a cohort of patients with muscle-invasive bladder cancer who either refused or were ineligible for...

Andrea Necchi, MD, discusses...

10/23/2024

Oncology

Conference Coverage

Durvalumab Added to Neoadjuvant Chemotherapy Improves Survival Outcomes in Muscle-Invasive Bladder Cancer: NIAGARA Trial

09/15/2024

Janelle Bradley ;

The NIAGARA trial showed that durvalumab plus neoadjuvant chemotherapy improved EFS and OS compared to neoadjuvant chemotherapy alone in patients with muscle-invasive bladder cancer.

The NIAGARA trial showed that...

09/15/2024

Oncology

News

Sacituzumab Govitecan Shows Potential Among Patients With Locally Advanced or Metastatic Urothelial Cancer

09/10/2024

Stephanie Holland ;

According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...

According to results from Cohort...

09/10/2024

Oncology

News

Pembrolizumab Monotherapy Shows Promise Among Patients With BCG-Unresponsive, High-Risk NMIBC With Papillary Tumors, Without Carcinoma in Situ

05/22/2024

Stephanie Holland

According to results from cohort B of the phase 2 KEYNOTE-057 trial, pembrolizumab monotherapy demonstrated promising activity with manageable toxicity among patients with Bacillus Calmette-Guerin–unresponsive, high-risk non-muscle invasive...

According to results from cohort...

05/22/2024

Oncology

FDA Approval

FDA Approves Nogapendekin Alfa Inbakicept for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer

04/23/2024

Stephanie Holland

Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.

Based on results from the phase...

04/23/2024

Oncology

Videos

Navigating the Bacillus Calmette-Guerin Shortage for Patients With High-Risk Non-Muscle Invasive Bladder Cancer

04/08/2024

Featuring Andrew Katims, MD, MPH

Featuring Andrew Katims, MD, MPH ...

Andrew Katims, MD, discusses the challenges of treating patients with high-risk non-muscle invasive bladder cancer during the bacillus Calmette-Guerin shortage.

Andrew Katims, MD, discusses the...

04/08/2024

Oncology

News

Pembrolizumab Monotherapy Shows Promise Among Patients With BCG-Unresponsive, High-Risk NMIBC With Papillary Tumors, Without Carcinoma in Situ

05/22/2024

Stephanie Holland

According to results from cohort...

05/22/2024

Oncology

FDA Approval

FDA Approves Nogapendekin Alfa Inbakicept for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer

04/23/2024

Stephanie Holland

Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.

Based on results from the phase...

04/23/2024

Oncology

News

FDA Grants Approval for Nivolumab Plus Cisplatin and Gemcitabine for Unresectable or Metastatic Urothelial Carcinoma in First-Line Setting

03/08/2024

Allison Casey

On March 7, 2024, the FDA approved nivolumab plus gemcitabine and cisplatin for patients with unresectable or metastatic urothelial carcinoma in the first-line setting.

On March 7, 2024, the FDA...

03/08/2024

Oncology

Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center

News

Enfortumab Vedotin Plus Pembrolizumab Beats Chemotherapy for Survival Outcomes Among Patients With Untreated Advanced Urothelial Carcinoma

03/07/2024

Allison Casey ;

According to a phase 3 study, enfortumab vedotin plus pembrolizumab significantly improved progression-free survival and overall survival compared to chemotherapy among patients with untreated advanced urothelial carcinoma.

According to a phase 3 study,...

03/07/2024

Oncology

News

Further Support for Adjuvant Chemotherapy for Upper Tract Urothelial Cancer

02/29/2024

Allison Casey ;

Final, updated results from the phase 3 POUT trial added further support to the use of adjuvant chemotherapy for patients with upper tract urothelial cancer who have undergone nephroureterectomy.

Final, updated results from the...

02/29/2024

Oncology

News

Modified BCG Regimen Yields Acceptable Oncologic Outcomes Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer

02/29/2024

Allison Casey ;

According to 5-year follow-up data from a phase 2 trial, the use of 2 induction courses of bacillus Calmette-Guèrin without maintenance therapy may provide an alternate treatment option for patients with high-risk non-muscle-invasive bladder...

According to 5-year follow-up...

02/29/2024

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Shows Promise in Platinum-Refractory/Relapsed Metastatic Urothelial Carcinoma

02/15/2024

Allison Casey ;

According to a primary analysis of a cohort from the phase 3 TROPHY-U-01 trial, sacituzumab govitecan plus pembrolizumab showed promising antitumor activity with a manageable toxicity profile among patients with metastatic urothelial cancer...

According to a primary analysis...

02/15/2024

Oncology

Andrea Apolo, MD, National Cancer Institute

Conference Coverage

Adjuvant Pembrolizumab New Therapeutic Option For High-Risk Muscle-Invasive Bladder Cancer

02/05/2024

Andrea Apolo , MD;

At the 2024 ASCO GU Cancers Symposium, Andrea Apolo, MD, shared insights from the phase 3 AMBASSADOR Alliance AO31501 study, looking at adjuvant pembrolizumab for patients with muscle-invasive bladder cancer at a high risk for recurrence.

At the 2024 ASCO GU Cancers...

02/05/2024

Oncology

Conference Coverage

HER2 and PD-L1 Immunohistochemistry Expression Among Patients With Advanced Bladder Cancer

01/30/2024

David Aggen , MD, PhD;

David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...

David Aggen, MD, shares insights...

01/30/2024

Oncology

Conference Coverage

Enfortumab Vedotin Plus Pembrolizumab Potential New Standard of Care for Advanced Urothelial Carcinoma in the First-Line Setting

01/26/2024

Michiel van der Heijden , MD;

Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.

Michiel van der Heijden, MD,...

01/26/2024

Oncology

Interactive Features

Quiz

Enfortumab Vedotin for Patients With Advanced Urothelial Carcinoma

10/19/2023

True or False: According to findings from the phase 3 EV-301 trial, enfortumab vedotin maintained clinically meaningful overall survival benefit at a median follow-up of approximately 2 years, compared with chemotherapy, among patients with...

True or False: According to...

10/19/2023

Oncology

Quiz

NECTIN-4 Expression During Metastatic Spread in Urothelial Carcinoma

02/10/2023

In a study evaluating the changes in membranous NECTIN-4 protein expression among urothelial carcinoma progression, what percentage of cases demonstrated a decrease of NECTIN-4 expression during metastatic spread?

In a study evaluating the...

02/10/2023

Oncology

Quiz

Quiz: Rogaratinib Compared With Standard Chemotherapy for FGFR-Altered Urothelial Carcinoma

12/01/2022

In the open-label, multicenter FORT-1 trial, how did the pan-FGFR inhibitor rogaratinib compare to standard chemotherapy, in terms of efficacy in treating patients with FGFR-altered urothelial carcinoma?

In the open-label, multicenter...

12/01/2022

Oncology

Quiz

Quiz: Following TURBT, which treatment was found to be a safe, effective alternative to BCG for patients with NMIBC?

10/18/2022

Following transurethral resection of bladder tumor, which treatment was found to be an effective and safe alternative to bacillus Calmete-Guérin for patients with non-muscle invasive bladder cancer?

Following transurethral...

10/18/2022

Oncology

Quiz

Quiz: Radical Cystectomy vs Intravesical Therapy for Non-Muscle Invasive Bladder Cancer

09/02/2022

What was the difference in survival found between patients with non-muscle invasive bladder cancer who underwent radical cystectomy vs those who underwent intravesical therapy, within 12 months of receiving BCG?

What was the difference in...

09/02/2022

Oncology

Test Your Knowledge

Quiz: Which Phase 2 Trial Led to the Approval of Sacituzumab Govitecan for aUC?

02/20/2022

The approval of sacituzumab govitecan for patients with advanced urothelial cancer was based on which phase 2 trial?

The approval of sacituzumab...

02/20/2022

Oncology

Quiz

Quiz: Which Immunotherapy Drug Treats Advanced or Metastatic Urothelial Cancer?

07/01/2021

Which immunotherapy drug was recently granted accelerated approval by the FDA to treat adult patients with locally advanced or metastatic urothelial cancer?

Which immunotherapy drug was...

07/01/2021

Oncology

Quiz

Quiz: Does Nivolumab Provide the Longest DFS Rate for Urothelial Carcinoma?

07/01/2021

In a recent trial that evaluated various treatments for patients with high-risk muscle-invasive urothelial carcinoma, adjuvant nivolumab provided the longest disease-free survival rate.

In a recent trial that evaluated...

07/01/2021

Oncology

Test Your Knowledge

Quiz: Risk of Recurrence and Progression for Patients with NMIBC

02/19/2021

In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?

In patients with NMIBC, does...

02/19/2021

Oncology

Test Your Knowledge

Quiz: Which Treatment Received FDA Approval for Metastatic Urothelial Carcinoma?

11/03/2020

What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?

What treatment was approved by...

11/03/2020

Oncology

Recent News

News

Pembrolizumab Monotherapy Shows Promise Among Patients With BCG-Unresponsive, High-Risk NMIBC With Papillary Tumors, Without Carcinoma in Situ

05/22/2024

Stephanie Holland

According to results from cohort...

05/22/2024

Oncology

FDA Approval

FDA Approves Nogapendekin Alfa Inbakicept for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer

04/23/2024

Stephanie Holland

Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.

Based on results from the phase...

04/23/2024

Oncology

News

FDA Grants Approval for Nivolumab Plus Cisplatin and Gemcitabine for Unresectable or Metastatic Urothelial Carcinoma in First-Line Setting

03/08/2024

Allison Casey

On March 7, 2024, the FDA approved nivolumab plus gemcitabine and cisplatin for patients with unresectable or metastatic urothelial carcinoma in the first-line setting.

On March 7, 2024, the FDA...

03/08/2024

Oncology

News

Enfortumab Vedotin Plus Pembrolizumab Beats Chemotherapy for Survival Outcomes Among Patients With Untreated Advanced Urothelial Carcinoma

03/07/2024

Allison Casey ;

According to a phase 3 study,...

03/07/2024

Oncology

News

Further Support for Adjuvant Chemotherapy for Upper Tract Urothelial Cancer

02/29/2024

Allison Casey ;

Final, updated results from the phase 3 POUT trial added further support to the use of adjuvant chemotherapy for patients with upper tract urothelial cancer who have undergone nephroureterectomy.

Final, updated results from the...

02/29/2024

Oncology

News

Modified BCG Regimen Yields Acceptable Oncologic Outcomes Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer

02/29/2024

Allison Casey ;

According to 5-year follow-up...

02/29/2024

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Shows Promise in Platinum-Refractory/Relapsed Metastatic Urothelial Carcinoma

02/15/2024

Allison Casey ;

According to a primary analysis...

02/15/2024

Oncology

FDA Approval

FDA Approves Erdafitinib for Patients With Locally Advanced/Metastatic Urothelial Carcinoma Harboring FGFR3 Alterations

01/20/2024

Stephanie Holland ;

Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.

Based on results from cohort 1...

01/20/2024

Oncology

News

Tremelimumab Shows Potential Among Patients With PD-1/PD-L1–Resistant Metastatic Urothelial Cancer

01/12/2024

Allison Casey ;

According to a phase 2 trial, a high dose of tremelimumab showed modest activity and similar toxicity as previously reported among patients with PD-1/PD-L1–resistant metastatic urothelial cancer.

According to a phase 2 trial, a...

01/12/2024

Oncology

News

Endoluminal Gemcitabine-Docetaxel as a Renal-Sparing Option for Select Patients With High Grade Upper-Tract Urothelial Carcinoma

01/08/2024

Allison Casey ;

According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.

According to a retrospective...

01/08/2024

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology